Morinaga Milk Industry Co., Ltd. - With mum since 1917

Morinaga Milk Industry Co., Ltd. is one of the largest dairy companies in Japan and celebrated its 100th anniversary in 2017.

Morinaga Milk holds a leading marketing position with its many top brands in yogurt, milk, infant formula, beverage, cheese, butter, ice cream, pudding, dietary supplements and clinical foods. Morinaga Milk excels in innovative technology and offers not only dairy products, but also other beneficial functional ingredients to customers throughout the world. The functional ingredients manufactured and supplied globally by Morinaga Milk are probiotics, lactoferrin, lactulose, hydrolysate, whey proteins and lactose, which are used in high value-added nutritional products such as infant formulas, dietary supplements and in the field of sports nutrition.

Since Morinaga Milk was the first company to start producing and selling infant formulas in Japan, the company has a long, abundant history and experience with research and development of infant nutrition. Morinaga Milk started research of bifidobacteria in the1960s inspired by the fact that bifidobacteria are the predominant bacteria residing in the intestines of breast-fed infants. Below are the main strains of Morinaga Milk's probiotics.

BB536 is a flagship probiotics originated from healthy infants

Bifidobacterium longum BB536, the flagship probiotics of Morinaga Milk, is a strain of bifidobacteria living naturally in human intestines. BB536 is well-known for its stability, quality and wide-ranging effects, shown by 160 scientific reports, including numerous clinical studies. BB536 attained GRAS status (GRN 000268) in 2007 and has been used in more than 30 countries in the world for over 40 years.

One of the main effects shown by multiple clinical studies is maintenance of intestinal health. In one clinical study, 39 women prone to constipation consumed 100g of yogurt with BB536 for two weeks. Compared with general yogurt products containing only lactic acid bacteria, intake of yogurt with BB536 improved the stool frequency and reduced the level of ammonia in feces. Additional effects, including prevention of infection, anti-allergy benefits and others, have been described in clinical studies. Morinaga provides BB536 not only for dietary supplements and infant formulas, but also for cultures used in yogurt and yogurt drinks.

M-16V has been used in more than 100 NICU hospitals in Japan

Bifidobacterium breve M-16V is well-known for its strong safety profile and its efficacy in infants. M-16V's safety and its effect to promote healthy growth of premature infants are highly evaluated by medical professionals. M-16V has been used in more than 100 neonatal intensive care units (NICU) in hospitals throughout Japan. M-16V attained not only FDA-notified GRAS status, but also GRAS status for infants (GRN 000453 and GRN 000454) in 2013.

B-3 is a unique probiotics to reduce body fat

Bifidobacterium breve B-3 is a special bifidobacterium selected in light of the relationship between the gut microbiota and obesity. B-3 has a unique function that restores the intestinal barrier and inhibits chronic inflammation inside body which causes obesity. According to a DBPC study by Morinaga Milk, fifty-two men and women with high body mass indexes (BMI) consumed B-3 capsules for 12 weeks. The result showed that the amount of body fat was significantly decreased in the B-3 intake group compared to the placebo group.

M-63 is effective for improving irritable bowel syndrome symptoms

Bifidobacterium infantis M-63 is highly capable of utilizing human milk oligosaccharides in breast milk. M-63 is considered to be adapted to the intestinal environment of humans, especially infants. An in-vitro study found that M-63 can prevent the growth of rotavirus. A clinical study provides evidence that M-63 promotes the improvement of irritable bowel syndrome symptoms.

Human Residential Bifidobacteria is compatible with breast milk

Morinaga Milk has been conducting research on bifidobacteria for many years. The research shows that bifidobacteria naturally resides in the human intestine, especially in infants. Such bacteria are called Human Residential Bifidobacteria (HRB). The research also discovered that only HRB species are capable of certain functions. Unlike Non-HRB (Non-Human Residential Bifidobactera) species, HRB species are particularly effective at utilising the Human Milk Oligosaccharides (HMOs) in breast milk; the species can also tolerate lysozyme, a "natural antibacterial factor". These characteristics allow HRB species to colonise the infant gut, contributing to the development and maturation of a healthy microbiome. These findings show that HRBs are natural and suitable for consumption by adults and infants.

Lactobacillus species are also a key to our intestinal health

In addition to bifidobacteria, Morinaga provides some varieties of Lactobacillus, specifically Lactobacillus gasseri LAC-343, Lactobacillus acidophilus LAC-361 and Lactobacillus rhamnosus LCS-742. All three promote intestinal health and are safe and stable.

Morinaga Milk continues pursuing the safety and quality of itsprobiotics

Morinaga's highly safe bifidobacteria are manufactured at a facility which is both FSSC and Halal certified. The bacteria are free of dairy compounds, gluten, allergens and GMOs and are available in capsules, sachets, tablets, and in powder form for application in powdered drinks, cereals, chocolates, protein powder and so on. Morinaga Milk will continue to pursue research on bifidobacteria and to provide evidence-based products for making human life healthier.

If you wish to receive more detailed information about Morinaga's probiotics, please use the below form to send us your business inquiry.

Products and Services

Contact Details

Morinaga Milk Industry Co., Ltd.
Shiba 5-Chome
Tokyo 108-8384

Intestinal health maintenance, Infection prevention, anti-allergy functions, etc.
Health maintenance for low birth weight infants, anti-allergy functions.
Intestinal health maintenance, gut-brain axis.
Body fat reduction.
Make An Enquiry
First Name

Last Name

Email Address


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.